Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Depreciation: 2014-2018

Historic Accumulated Depreciation for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Dec 2018 value amounting to $3.1 million.

  • Viridian Therapeutics, Inc.\DE's Accumulated Depreciation was N/A to $3.2 million in Q1 2019 from the same period last year, while for Mar 2019 it was $3.2 million, marking a year-over-year change of. This contributed to the annual value of $3.1 million for FY2018, which is N/A change from last year.
  • Viridian Therapeutics, Inc.\DE's Accumulated Depreciation amounted to $3.1 million in FY2018, which was up 318.13% from $739,000 recorded in FY2015.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Accumulated Depreciation peaked at $3.1 million during FY2018, and registered a low of $555,000 during FY2014.
  • For the 1-year period, Viridian Therapeutics, Inc.\DE's Accumulated Depreciation averaged around $3.1 million, with its median value being $3.1 million (2018).
  • Data for Viridian Therapeutics, Inc.\DE's Accumulated Depreciation shows a peak YoY surged of 33.15% (in 2015) over the last 5 years.
  • Viridian Therapeutics, Inc.\DE's Accumulated Depreciation (Yearly) stood at $555,000 in 2014, then soared by 33.15% to $739,000 in 2015, then reached $3.1 million in 2018.